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Introduction {#sec1}
============

Autoinflammatory disorders caused by the dysfunction of proteasomes have been collectively designated as proteasome-associated autoinflammatory syndromes (PRAASs) ([@bib1], [@bib7], [@bib25]). PRAASs were originally defined as mutations in the immunoproteasome component of *proteasome subunit beta 8* (*PSMB8*) gene, but have been since expanded to include the dysregulation of both the constitutive proteasome and the immunoproteasome ([@bib7], [@bib25]). PRAASs include Nakajo-Nishimura syndrome (NNS; also known as autoinflammation, lipodystrophy, and dermatosis syndrome) ([@bib2]), Japanese autoinflammatory syndrome with lipodystrophy ([@bib18]), joint contractures, muscular atrophy, microcytic anemia, panniculitis-associated lipodystrophy syndrome ([@bib10]), and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome ([@bib8], [@bib20]). NNS is an autosomal recessive disorder caused by a homozygous mutation in the *PSMB8* gene ([@bib2], [@bib18]). Patients with NNS show pernio-like skin rashes from infancy and gradually develop partial lipodystrophy mainly in the face and upper extremities, as well as show characteristically long clubbed fingers with contracture of the interphalangeal joints. Patients also suffer from remittent fever and nodular erythema-like skin eruptions ([@bib2], [@bib19]). Although the administration of systemic corticosteroids is partially effective, particularly against skin lesions, the prognosis remains relatively poor since this therapy is ineffective on lipodystrophy. Since there is currently no curative therapy for NNS and most patients die as a result of respiratory or cardiac failure ([@bib2], [@bib15]), therapeutic advances for NNS are desired.

Proteasomes are highly efficient proteolytic machinery for degrading damaged or unnecessary proteins ([@bib42]). *PSMB8* gene encodes β5i protein, which is a subunit of a specialized type of proteasome named immunoproteasome. The catalytic component of the constitutive proteasome consists of three protease subunits: chymotrypsin-like enzyme β5, trypsin-like enzyme β2, and caspase-like enzyme β1 ([@bib27], [@bib33]). These three subunits correspond to immunoproteasome subunits β5i, β2i, and β1i, respectively. The immunoproteasome is constitutively expressed in hematopoietic cells ([@bib24], [@bib34]). In addition, in immune cells, immunoproteasome subunits are upregulated and replace their corresponding constitutive proteasome subunits upon stimulation with proinflammatory cytokines such as interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) ([@bib17], [@bib24]). The immunoproteasome has a role in processing endogenous peptides that are presented on major histocompatibility complex I molecules ([@bib11], [@bib33]).

Almost all Japanese NNS patients share the same homozygous point mutation, c.602G \> T, which causes substitution of glycine 201 to valine ([@bib2], [@bib19]). NNS-associated *PSMB8* mutations cause impaired assembly of the immunoproteasome, resulting in a reduction of immunoproteasome activity in immune cells. This impaired immunoproteasome activity causes an accumulation of ubiquitinated and oxidized proteins ([@bib2]) and is attributed to the elevation of the serum concentration of several proinflammatory cytokines and chemokines, such as IL-6, IP-10 and MCP-1 in NNS patients ([@bib2]). Although involvement of the p38 mitogen-activated protein kinase (p38 MAPK) pathway in the upregulation of proinflammatory cytokines was implicated in NNS patients ([@bib2]), the precise pathway harnessing immunoproteasome dysfunction to the overproduction of proinflammatory cytokines remains unclear.

Among PRAASs, CANDLE syndrome has recently been recognized as an IFN-driven disease and shows a prominent IFN signature ([@bib20]). A JAK inhibitor, baricitinib, is currently undergoing clinical trial (clinicaltrials.gov: [NCT01724580](ctgov:NCT01724580){#intref0010}) ([@bib14]). On the other hand, although NNS and CANDLE share the same responsible gene, whether NNS symptoms are also driven by the IFN pathway has not been clarified. To investigate the detailed mechanism and signal pathways in NNS as well as to seek potential therapeutic candidates, in the current study we focused on establishing a pluripotent stem cell (PSC) model using NNS patient-derived induced pluripotent stem cells (iPSCs) and isogenic controls. We then recapitulated the *in vitro* phenotypes of NNS by differentiating the iPSCs into myeloid cell lines (PSC-MLs) ([@bib12]). NNS-PSC-MLs showed reduced proteasome activity and increased production of IL-6, MCP-1, and IP-10. Since these phenotypes corresponded to those of patient-derived peripheral blood monocytes, we concluded that our *in vitro* NNS-iPSC model successfully recapitulated the patient condition. We then validated several compounds for ameliorating the proinflammatory responses of NNS. Our isogenic PSC models are useful for elucidating the pathophysiology of NNS and also for providing a platform for high-throughput drug screening.

Results {#sec2}
=======

Establishment of NNS-iPSCs and the Generation of Isogenic PSC Panels {#sec2.1}
--------------------------------------------------------------------

Dermal fibroblasts were obtained from three NNS patients who shared the same homozygous mutation of *PSMB8* gene ([Table S1](#mmc1){ref-type="supplementary-material"}, p.G201V \[c.602G \> T\]) ([@bib2]). The clinical features of all three NNS cases are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}. These fibroblasts were reprogrammed by introducing retroviral vectors encoding OCT3/4, SOX2, KLF4, and cMYC ([@bib39]). Two iPSC clones from each NNS patient were randomly selected and propagated. All iPSC clones showed a typical characteristic human embryonic stem cell (ESC)-like morphology ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and expressed PSC-specific markers NANOG and SSEA4 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The expression of residual transgenes was rarely detected ([Figure S1](#mmc1){ref-type="supplementary-material"}B). All iPSC clones also maintained a normal karyotype ([Figure S1](#mmc1){ref-type="supplementary-material"}C), and their pluripotency was confirmed by the formation of teratomas composed of all three germ layers ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The chymotrypsin-like activity of undifferentiated patient-derived iPSCs was comparable to that of the control PSCs even after IFN-γ and TNF-α stimulation ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Since all 6 NNS-iPSC clones from three individuals exhibited similar characteristics, including hematopoietic differentiation efficiency ([Table S2](#mmc1){ref-type="supplementary-material"}), we selected a representative iPSC clone from patient 1 (NNS1-1, hereafter referred to as NNS1-1 \[MT\]) and used it for the subsequent analysis. To precisely evaluate the mutant-specific phenotype, we attempted to generate isogenic iPSCs by correcting the corresponding *PSMB8* mutation using the CRISPR-Cas9 (D10A) nickase-mediated double-nicking system ([@bib32], [@bib46]) ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). We tested two single-guide RNA (sgRNA) sequences for each breakpoint and found that the sgRNA pair sg1-2/sg2-1 showed the highest rate of homozygous recombination-mediated gene replacement: out of three puromycin-resistant clones analyzed, one clone was heterozygously targeted and two clones were homozygously targeted ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Hereafter, we selected the homozygously targeted clone, referred to as NNS1-1 (WT), which was validated by a genomic PCR ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The loxP-flanked puromycin selection cassette was removed from each targeted iPSC clone by transient transfection with a vector expressing Cre recombinase. We also checked the T-to-G homozygous correction on exon 5 of the *PSMB8* gene by Sanger sequencing ([Figure S2](#mmc1){ref-type="supplementary-material"}D). In a similar way, we generated homozygous *PSMB8*-G201V knockin PSCs from a control human ESC line, KhES-1 (referred to as KhES-1 \[WT\] for control KhES-1, and KhES-1 \[MT\] for *PSMB8*-mutated KhES-1; [Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}E--S2G). It was previously shown that the selective inhibition of two immunoproteasome subunits (β1i and β5i) results in the downregulation of several pluripotency markers in human ESCs ([@bib3]), indicating immunoproteasome subunits may affect the maintenance of pluripotency. However, in our hands, there was no difference in the expression of PSC-associated markers and *in vivo* pluripotency between MT- and WT-clones ([Figures S1](#mmc1){ref-type="supplementary-material"}A, S1B, and S1D). The efficiency of reprogramming and the efficiency of genome editing were also comparable between MT- and WT-clones ([Table S2](#mmc1){ref-type="supplementary-material"} and [Figures S2](#mmc1){ref-type="supplementary-material"}C and S2F). Therefore, at least in this study, the disease-associated mutant *PSMB8* seemed not to affect the biological features of undifferentiated PSCs. Overall, we successfully established isogenic disease-control pairs using patient-derived iPSCs and genome-editing technology, which enabled us to precisely evaluate the effects of the disease-causing *PSMB8* mutation in PSC-derived differentiated cells.Figure 1The Establishment of an Isogenic PSC Panel for NNS Study(A) Study design.(B) The protocol for monocytic differentiation and the establishment of PSC-MLs.(C--E) The chymotrypsin-like activity of PSC-MLs was measured by a luciferase-based assay. The chymotrypsin-like activity was normalized according to the number of cells. The chymotrypsin-like proteolytic activities of constitutive proteasome (D, β5 subunit) and immunoproteasome (E, β5i subunit) in PSC-MLs. Background fluorescence or luminescence was subtracted from each value. Bars indicate the means ±SD (n = 3). Asterisks indicate statistically significant differences by Student's t test: ^∗^p \< 0.05; ^∗∗^p \< 0.01.(F) Western blotting of immunoproteasome subunits β5i and α6.(G) The quantity of mature β5i in (F) was normalized by the expression of immature β5i.(H) Western blotting of ubiquitinated proteins.In (C)--(H), the cells were treated with IFN-γ (100 ng/mL) and TNF-α (100 ng/mL) for 20 hr.

Impairment of Immunoproteasome Activity in *PSMB8*-Mutant PSC-Derived Monocytic Cell Lines {#sec2.2}
------------------------------------------------------------------------------------------

Previous histopathological examination of the inflammatory sites in NNS patients has shown the infiltration of CD68^+^, myeloperoxidase-positive monocytic cells and CD3^+^ T cells ([@bib19]). Since macrophages are the primary source of inflammatory cytokines and predominantly express the immunoproteasome ([@bib9], [@bib24]), we focused on the *in vitro* phenotypes of differentiated monocytic cells from PSCs. CD14^+^ monocytes were differentiated from PSCs according to a previously described protocol with approximately 90% purity ([Figures 1](#fig1){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A) ([@bib43]). To stably obtain an unlimited number of differentiated cells, PSC-derived monocytes were immortalized by transducing lentivirus vectors that encoded MDM2, BMI1, and cMYC ([@bib12], [@bib16]) ([Figure 1](#fig1){ref-type="fig"}B). The established PSC-derived monocytic cell lines (PSC-MLs) maintained the expression of monocyte markers CD14 and CD33 ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and showed a morphology that was compatible with monocytic cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We measured the proteasome activity, especially the chymotrypsin-like activity in PSC-MLs, using a luciferase-based proteasome assay. When the immunoproteasome assembly was induced by IFN-γ and TNF-α, we observed an upregulation of chymotrypsin-like activity in wild-type PSC-MLs (WT-MLs) ([Figure 1](#fig1){ref-type="fig"}C). However, this upregulation was not observed in mutant PSC-MLs (MT-MLs) ([Figure 1](#fig1){ref-type="fig"}C). When the activity levels of β5 and β5i were separately evaluated in the IFN-γ- and TNF-α-treated PSC-MLs, we found the activity of constitutive subunit β5 was not affected in any PSC-ML ([Figure 1](#fig1){ref-type="fig"}D). In contrast, although treatment of WT-MLs with IFN-γ and TNF-α elevated the immunoproteasome subunit β5i activity, the activity was significantly lower in NNS1-1-(MT)-MLs, and there was no elevation in β5i activity in KhES-1-(MT)-MLs ([Figure 1](#fig1){ref-type="fig"}E). Notably, the baseline activity of β5i was already decreased in both MT-MLs ([Figure 1](#fig1){ref-type="fig"}E), possibly due to the constitutive expression of immunoproteasome proteins in hematopoietic cells ([@bib24]). The decreased chymotrypsin-like activity in IFN-γ- and TNF-α-treated cells was confirmed in primary monocytes from NNS patients ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Since all proteasome β subunits except β3 and β4 are translated as precursors containing N-terminal pro-regions ([@bib45]), we next evaluated the maturation of β5i protein in PSC-MLs. When untreated, β5i was constitutively expressed in both WT-MLs and MT-MLs, but its maturation was relatively impaired in MT-MLs ([Figures 1](#fig1){ref-type="fig"}F and 1G). Other proteasome subunits were also expressed in PSC-MLs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). When treated with IFN-γ and TNF-α, the maturation of β2i and β1i was also impaired in MT-MLs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). MT-MLs showed an accumulation of ubiquitinated proteins in comparison with WT-MLs not only with IFN-γ and TNF-α stimulation, but also in an untreated state ([Figure 1](#fig1){ref-type="fig"}H). These data support the physiological dysfunction of the immunoproteasome machinery in *PSMB8*-mutant PSC-derived monocytic cells.

Immunoproteasome Deficiency Causes an Aberrant Proinflammatory Response in MT-MLs {#sec2.3}
---------------------------------------------------------------------------------

We next investigated the cytokine and chemokine secretion profiles in PSC-MLs. IFN-α and IFN-β production was not observed in either WT-MLs or MT-MLs following IFN-γ and TNF-α or LPS stimulation (data not shown). IL-10 and IL-1β were also not detected in either WT-MLs or MT-MLs following IFN-γ and TNF-α stimulation (data not shown). However, IFN-γ and TNF-α stimulation significantly increased the secretion of proinflammatory cytokine IL-6 and proinflammatory chemokine MCP-1 in MT-MLs in comparison with the isogenic WT-ML counterparts ([Figure 2](#fig2){ref-type="fig"}A). Since an elevated IFN signature has been observed in other *PSMB8*-assocated autoinflammatory diseases ([@bib8], [@bib20]), we next measured the secretion of an IFN-responsive chemokine, IP-10. The secretion of IP-10 in MT-MLs and WT-MLs did not differ to a statistically significant extent following IFN-γ and TNF-α stimulation ([Figure 2](#fig2){ref-type="fig"}B). However, upon stimulation with only type II (IFN-γ) or type I (IFN-α) IFN, MT-MLs secreted a significantly higher amount of IP-10 in comparison with WT-MLs ([Figure 2](#fig2){ref-type="fig"}C). Both type I and type II IFNs induced the robust secretion of IP-10. We therefore focused on the effect of type II IFN in the subsequent analysis. The increased production of IL-6 and IP-10 was confirmed with primary monocytes obtained from NNS patients ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Since the excessive secretion of these cytokine and chemokines from MT-MLs corresponds to previous serum cytokine levels in NNS patients ([@bib2]), we considered our PSC-based *in vitro* model as having successfully recapitulated the cellular phenotypes of monocytic cells with an NNS-associated *PSMB8* mutation.Figure 2Functional Properties of PSC-MLs(A and B) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs in response to treatment with IFN-γ (100 ng/mL) and TNF-α (100 ng/mL) for 20 hr. Bars indicate the means ±SD (*n* = 3). Asterisks indicate statistically significant differences by Student's t test: ^∗^p \< 0.05; ^∗∗^p \< 0.01.(C) The amount of IP-10 secreted in response to treatment with type II (IFN-γ, 100 ng/mL) or type I IFN (IFN-α) for 20 hr. Bars indicate the means ±SD (*n* = 3).(D) A principal component analysis based on normalized RNA-seq data. Each symbol indicates each clone and treatment.(E) Gene set enrichment analysis. Gene sets that were significantly (false discovery rate \<0.25) enriched in MT-MLs treated with IFN-γ and TNF-α are shown.(F and G) Heat maps of genes belonging to gene ontologies associated with type I (F) and type II (G) IFN responses. Columns are mean-centered with relative abundance represented by color (blue, lower abundance; red, higher abundance).

Untreated and Stimulated MT-MLs Show Distinct Proinflammatory Transcriptional Profiles {#sec2.4}
--------------------------------------------------------------------------------------

To reveal the specific inflammatory signatures of MT-MLs, we next performed RNA-sequencing (RNA-seq) analysis of the PSC-MLs. Most of the proteasome subunits, including β5i, β2i, and β1i, were upregulated upon IFN-γ and TNF-α treatment in both MT- and WT-MLs ([Figure S3](#mmc1){ref-type="supplementary-material"}F). On the other hand, the expression of IFN-α or IFN-β genes was not detected even under the stimulated condition ([Figure S3](#mmc1){ref-type="supplementary-material"}G). A principal component analysis from the normalized gene counts showed that the samples were clearly grouped according to the genotypes of *PSMB8* and stimulation ([Figure 2](#fig2){ref-type="fig"}D). MT-MLs and WT-MLs were distinguished even when untreated, indicating that *PSMB8*-mutant cells were in a "primed" state before stimulation. In order to extract differences in the regulation of the pathways in MT-MLs and WT-MLs, we performed a gene set enrichment analysis ([@bib38]). Upon IFN-γ and TNF-α treatment of the MT-MLs, several inflammatory pathways, in particular interferon-associated pathways including "INTERFERON_GAMMA_RESPONSE,\" "INTERFERON_ALPHA_RESPONSE," and "TNF-A_SIGNALING_VIA_NF-κB," were significantly enriched (false discovery rate \< 0.25; p \< 0.01) in comparison with WT-MLs ([Figure 2](#fig2){ref-type="fig"}E). Especially, genes associated with type I and type II IFN responses were upregulated in MT-MLs ([Figures 2](#fig2){ref-type="fig"}F and 2G). These results suggest that the aberrant expression of genes, cytokines, and chemokines is associated with the *PSMB8* mutation even in an untreated state as well as in response to IFN-γ and TNF-α stimulation.

Since the NNS-associated *PSMB8* mutation is considered hypo-functional, we next wondered whether pharmacological inhibition of β5i could mimic the *in vitro* phenotypes of NNS. For this experiment, we pretreated PSC-MLs with a selective β5i inhibitor, ONX-0914 ([@bib26]), and evaluated the cytokine production. ONX-0914 decreased the chymotrypsin-like activity of WT-MLs stimulated with IFN-γ and TNF-α ([Figure S4](#mmc1){ref-type="supplementary-material"}A). While a low dose of ONX-0914 increased the secretion of IL-6 and MCP-1, a high dose showed an anti-correlative inhibitory effect on the secretion of IL-6 and MCP-1, even though the chymotrypsin-like activity was inhibited ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). On the other hand, the secretion of IP-10 from WT-MLs was reduced by pretreatment with ONX-0914 ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Since *PSMB8*-mutant MLs showed a consistent increase in the secretion of these cytokines, these results are inconsistent with findings in NNS patients. The reason for this discrepancy is currently unknown, but we suppose it is associated with specific mutant *PSMB8* functions. Nevertheless, these data underscore the significance of mutant models instead of pharmacological models for the study of the NNS pathophysiology.

Effects of a Series of Anti-inflammatory Compounds on PSC-MLs Reveal the Specific Inflammatory Pathway in NNS {#sec2.5}
-------------------------------------------------------------------------------------------------------------

Because the cytokine assays and RNA-seq data indicated the activation of inflammatory pathways in MT-ML lines, we evaluated the effects of several anti-inflammatory compounds on IFN-γ- and TNF-α-treated PSC-MLs. First, PSC-MLs were pretreated with an anti-inflammatory corticosteroid, dexamethasone, which inhibits the activation of the NF-κB and MAPK pathways ([@bib5]). Dexamethasone slightly reduced the secretion of IL-6 and MCP-1, but not in all PSC-MLs, while the level of IP-10 was not affected ([Figure 3](#fig3){ref-type="fig"}A). Next, we attempted to inhibit downstream of the IFN pathway by using a pan-JAK inhibitor, tetracyclic pyridone 6 (P6) ([@bib21], [@bib30]), a potent, cell-permeable, and ATP competitive inhibitor of JAK1, JAK2, JAK3, and Tyk2. P6 inhibited the secretion of IP-10, IL-6, and MCP-1 in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}B). We also evaluated the effect of another JAK inhibitor, baricitinib, on IFN-γ- and TNF-α-treated PSC-MLs, because it is an approved drug and a clinical trial of baricitinib for CANDLE syndrome is ongoing ([@bib14]). As expected, baricitinib inhibited the secretion of IP-10, IL-6, and MCP-1 in a dose-dependent manner ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 3Effects of Anti-inflammatory Compounds on IFN-γ- and TNF-α-Treated PSC-MLs(A--E) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated 3 hr with the indicated compounds and subsequently treated with IFN-γ and TNF-α (A--C) or IFN-γ only (D and E) for 20 hr. Bars indicate the means ±SD (n = 3). Asterisks indicate statistically significant differences by Student's t test: ^∗^p \< 0.05; ^∗∗^p \< 0.01.

Since the enhanced phosphorylation of p38 MAPK in inflamed tissue was observed in NNS patients ([@bib2]), we wondered whether the enhanced p38 MAPK pathway was responsible for the proinflammatory response in MT-MLs. We therefore evaluated the effect of SB202190, a p38 MAPK inhibitor ([@bib23]). SB202190 inhibited the secretion of IL-6, IP-10, and MCP-1 in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}C). Intriguingly, SB202190 and P6 showed similar potency at inhibiting the secretion of IP-10 and MCP-1 even under stimulation by IFN-γ alone ([Figures 3](#fig3){ref-type="fig"}D and 3E), indicating the possibility of pathological crosstalk between the IFN pathway and the p38 MAPK pathway in MT-MLs.

Excessive Production of Reactive Oxygen Species in MT-MLs Contributes to Proinflammatory Responses through Activation of the p38 MAPK and IFN-γ Pathways {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Impaired immunoproteasome activity can cause an abnormal accumulation of proteins and might therefore cause various stresses in cells. Proteasome dysfunction due to the use of the chemical inhibitor bortezomib causes damage to the mitochondria, leading the cells to increase their production of reactive oxygen species (ROS), which results in cytosolic oxidation ([@bib22]). Oxidative stress can cause an increased production of inflammatory cytokines and chemokines ([@bib28]). Indeed, the intracellular production of ROS is increased in MT-MLs regardless of IFN-γ and TNF-α stimulation ([Figures 4](#fig4){ref-type="fig"}A and 4B). We therefore examined the effects of antioxidants on the production of cytokines and chemokines. The pretreatment of PSC-MLs with glutathione-SH (GSH) before IFN-γ and TNF-α stimulation reduced the secretion of IL-6 and MCP-1 ([Figure 4](#fig4){ref-type="fig"}C). In the presence of another antioxidant, N-acetyl-cysteine (NAC), the secretion of IL-6, MCP-1, and IP-10 was also significantly reduced ([Figure 4](#fig4){ref-type="fig"}D). Of note, higher concentrations of GSH or NAC markedly or completely inhibited the secretion of these cytokines and chemokines ([Figures 4](#fig4){ref-type="fig"}C and 4D). Interestingly, GSH and NAC also potently inhibited the secretion of IP-10 and MCP-1, even under stimulation with IFN-γ alone, indicating the contribution of ROS in the IFN-γ pathway in NNS ([Figures 4](#fig4){ref-type="fig"}E and 4F). Overall, these data indicate the important role that excessive ROS production plays in the proinflammatory response of NNS patient-derived monocytic cells. In previous reports, intracellular ROS was found to be an essential second messenger in various signal cascades ([@bib44]). Proteasome dysfunction-mediated ROS can enhance the activation of the p38 MAPK pathway ([@bib22], [@bib36]), and the JAK/STAT pathway responds to intracellular ROS upon stimulation ([@bib35]). Indeed, the phosphorylation of p38 MAPK in NNS patient lymphocytes was greater than that in healthy controls ([@bib2], [@bib18]). Higher levels of phosphorylated STAT1 (pY701) and p38 MAPK (pT180/Y182) were observed in MT-MLs as well, even in an untreated state ([Figure 5](#fig5){ref-type="fig"}A), as too was the constitutive expression of p38 MAPK in MT-MLs ([Figure 5](#fig5){ref-type="fig"}A). The increased phosphorylation of STAT1 in untreated MT-MLs was ameliorated by NAC treatment ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, even in the stimulated condition, NAC treatment reduced the ratio of phospho-STAT1/total STAT1 in NNS patient-derived MT-MLs ([Figure 5](#fig5){ref-type="fig"}B). To elucidate the source of the ROS production, we next measured the production of mitochondrial ROS by using MitoSOX. Mitochondrial ROS was consistently increased in MT-MLs ([Figures 5](#fig5){ref-type="fig"}C and 5D). On the other hand, a NOX (NADPH oxidase) enzyme inhibitor, Apocynin, failed to inhibit ROS production or the secretion of IL-6, MCP-1, and IP-10 in all samples ([Figures 5](#fig5){ref-type="fig"}E--5G). Therefore, at least in our iPSC-based system, the primary source of ROS in MT-MLs seems to be mitochondria rather than NOX enzymes. This finding is consistent with a previous report that concluded the elevated ROS upon proteasomal inhibition originated from mitochondria ([@bib22]).Figure 4*PSMB8*-Mutant PSC-MLs Show Enhanced ROS Production(A and B) ROS production in untreated PSC-MLs or those stimulated with IFN-γ with/without TNF-α measured by CellROX. Flow diagram (A) and quantification by mean fluorescence intensity (MFI) are shown (B).(C and D) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated for 3 hr with the indicated antioxidants and subsequently treated with IFN-γ and TNF-α for 20 hr.(E and F) The amount of MCP-1 and IP-10 secreted from PSC-MLs. Cells were pretreated for 3 hr with the indicated antioxidants and subsequently treated with IFN-γ for 20 hr. IL-6 was not detected in this condition. Bars indicate the means ±SD (n = 3).Asterisks indicate statistically significant differences by Student's t test: ^∗^p \< 0.05; ^∗∗^p \< 0.01.Figure 5Enhanced Production of Mitochondrial ROS and Activation of the JAK/STAT Pathway in MT-MLs(A) Western blotting analysis of whole-cell lysates of PSC-ML lines probed for total and phosphorylated STAT1 (pY701) or total and phosphorylated p38 MAPK (pT180/pY182). PSC-ML lines were pretreated with NAC for 3 hr and then with IFN-γ for 1 hr.(B) Densitometric quantification of western blot bands of only the IFN-γ condition in (A). The NAC-treated group was measured by the fold change in the phosphorylation of STAT1/total STAT1 relative to the corresponding untreated group.(C and D) Mitochondrial ROS production in PSC-MLs untreated or treated with IFN-γ with/without TNF-α measured by MitoSOX. Flow diagram (C) and quantification by mean fluorescence intensity (MFI) (D) are shown.(E and F) ROS production in PSC-MLs untreated or treated with IFN-γ with/without TNF-α measured by CellROX in response to a NOX inhibitor, apocynin. Flow diagram (E) and quantification by MFI (F) are shown.(G) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated 3 hr with apocynin and subsequently treated with IFN-γ and TNF-α for 20 hr. (D, F, and G) Bars indicate the means ±SD (n = 3).

Consequently, MT-MLs in the untreated state exhibited a "primed" state that coincides with excessive ROS production and with an inordinate amount of constitutively expressed STAT1. Engagement of the JAK/STAT and p38 MAPK pathways followed by IFN-γ and TNF-α stimulation in MT-MLs therefore elicited an augmented production of inflammatory cytokines and chemokines, part of which is mediated by the excessive production of ROS.

Discussion {#sec3}
==========

Recent advances in the field of proteasome diseases, including NNS, have revealed a critical connection between the dysregulation of the immunoproteasome and autoinflammation. However, the direct cause of the potent inflammation has not been fully elucidated. We herein established a panel of isogenic PSC clones by CRISPR/Cas9-mediated genome editing the *PSMB8* gene, which enabled us to precisely evaluate the *in vitro* phenotypes of PSC-derived differentiated progenies. We found that elevated ROS levels in MT-MLs have a pivotal role in the proinflammatory response and can be ameliorated by antioxidant therapy ([Figure 6](#fig6){ref-type="fig"}). Our PSC-based models therefore provide a possible alternative therapeutic option for NNS patients and may serve as a platform for seeking potential candidate compounds for medical use.Figure 6A Proposed Model of Autoinflammation Induced by *PSMB8* with the NNS-Associated Mutation

PRAASs are usually characterized by a type I IFN response. The primary source of type I IFN in CANDLE patients appears to be plasmacytoid dendritic cells (pDCs) ([@bib7]), but it is unknown whether the production of these cytokines is upregulated in the pDCs of NNS patients ([@bib2]). Investigation should be given to whether pDCs from NNS-patient-derived iPSCs produce increased amounts of type I IFN, but currently there exists no reliable differentiation method from hPSCs toward pDCs. In the present study, we focused on the proinflammatory roles of monocytic cells in NNS rather than the production of type I or type II IFNs. We established the *in vitro* phenotypes of monocytic cells derived from PSCs and confirmed that these cells produce significant amounts of proinflammatory cytokines and chemokines under conditions that induce the immunoproteasome, suggesting a distinct role of these cells for maintaining the proinflammatory response in NNS.

Untreated MT-MLs showed lower chymotrypsin-like enzymatic activity than WT-MLs based on the constitutive expression of β5i ([Figures 1](#fig1){ref-type="fig"}E--1G). This observation is in line with previous findings that describe the constitutive expression of immunoproteasome components in hematopoietic cells, including monocytes, macrophages, B cells, and dendritic cells ([@bib17], [@bib24]). In our PSC-derived model, MT-MLs showed excessive production of ROS even in an untreated state, probably because of the constitutive accumulation of ubiquitinated proteins, which induced cellular stress ([Figure 1](#fig1){ref-type="fig"}H). Indeed, proteasome dysfunction is known to cause mitochondrial damage and subsequent mitochondrial and cellular ROS production ([@bib22]). The excessive production of superoxide species then activates MAPK family molecules ([@bib4]) and the JAK/STAT cascade ([@bib35]), thereby causing a proinflammatory response by upregulating downstream inflammatory cytokines. Indeed, the enhanced phosphorylation of STAT1 was observed in untreated MT-MLs ([Figure 5](#fig5){ref-type="fig"}A), which is consistent with findings in NNS patient-derived fibroblasts, transformed B cells, and peripheral blood lymphocytes ([@bib2], [@bib18]). Our data support the hypothesis that the excessive production of ROS is one of the direct downstream consequences of abnormal immunoproteasome function, connecting cellular stress to the activation of the proinflammatory pathway.

In our model, ROS played a critical role in the excessive production of proinflammatory cytokines and chemokines, because antioxidative treatment inactivated the production of IL-6, MCP-1, and IP-10 through the p38 MAPK or JAK/STAT pathways. However, whether these pathways are necessary and sufficient for the pathogenesis of NNS remains to be elucidated, as proteasome dysregulation also causes other cellular stresses, such as endoplasmic reticulum stress ([@bib29]). Since antioxidant treatment did not reduce the accumulation of ubiquitinated proteins ([@bib22]), a therapeutic approach that leads to the recovery of both cytokine overproduction and proteasome dysfunction could be required. Since the modulation of proteasome activity can be a promising therapeutic strategy for a variety of diseases ([@bib13]) and the dysfunction of chymotrypsin-like proteasome activity is considered a primary cause of NNS ([@bib15]), we also tried to enhance chymotrypsin-like proteasome activity with betulinic acid (BA). The application of BA led to the recovery of the chymotrypsin-like activity in both MT- and WT-MLs in a dose-dependent manner ([Figure S6](#mmc1){ref-type="supplementary-material"}A). However, the cytokine and chemokine production was not reduced in BA-treated PSC-MLs ([Figure S6](#mmc1){ref-type="supplementary-material"}B), possibly due to BA off-target effects, such as activation of the p38 MAPK pathway ([@bib40]). Consistent with a previous report ([@bib41]), BA also failed to recover the constitutive accumulation of ubiquitinated proteins in MT-MLs ([Figure S6](#mmc1){ref-type="supplementary-material"}C). These data indicate that, although it could upregulate chymotrypsin-like proteolytic activities, BA is insufficient for recovering the phenotypes associated with the disease-associated mutation. Therefore, further efforts are required to identify compounds that are effective at recovering immunoproteasome activities and resolving ubiquitinated proteins. We believe that our PSC-ML-based model can serve as a platform for high-throughput screening for finding these compounds, because this system enables functional assays to investigate the production of cytokines and the function of proteasomes in 96- or 384-well plates using immortalized PSC-MLs.

Interestingly, a JAK inhibitor, P6, suppressed the secretion of IL-6 and MCP-1, both of which are mainly dependent on activation of the MAPK pathway ([Figures 3](#fig3){ref-type="fig"}B and 3D). On the other hand, a p38 MAPK inhibitor, SB202190, reduced not only the secretion of IL-6 and MCP-1, but also that of IP-10, which is mainly dependent on activation of the JAK/STAT pathway ([Figures 3](#fig3){ref-type="fig"}C and 3E). IFN-dependent production of IP-10 was suppressed by SB202190 even without TNF-α stimulation ([Figure 3](#fig3){ref-type="fig"}E). A part of this crosstalk seemed to occur under the influence of increased ROS, because an antioxidant, NAC, resolved the hyper-phosphorylation of STAT1 in unstimulated MT-MLs. Although the enhancement of STAT-dependent transcription by activation of the p38 MAPK pathway has been reported ([@bib31]), ROS-induced simultaneous activation of the p38 MAPK and JAK/STAT pathways has not. ROS may be a second messenger that enhances the p38 MAPK pathway, as NAC reduced the downstream cytokine production without affecting p38 MAPK phosphorylation ([Figures 5](#fig5){ref-type="fig"}A and 5B). Since the therapeutic use of p38 MAPK inhibitors or JAK inhibitors can be associated with severe side effects, such as secondary immune deficiency ([@bib6], [@bib37]), our results may support the possible use of antioxidants as an alternative therapeutic option for NNS and related immunoproteasome disorders ([Figure 6](#fig6){ref-type="fig"}).

Although progressive lipomuscular atrophy is an important phenotype that affects the quality of life of NNS patients, findings related to the functional roles of immunoproteasomes in affected tissues are relatively limited. Since PSCs can differentiate into other affected cells, such as myotubes and adipocytes, the tissue- or cell-type-specific pathophysiology of NNS can be explored using these progenies. The co-culturing of non-hematopoietic cells with PSC-derived immune cells will provide an opportunity for dissecting the cell-autonomous and non-cell-autonomous pathological mechanisms in muscle and adipose tissues. Our PSC-based methods can also be applicable to PRAAS. The validation of candidate compounds with these PSC-derived progenies is therefore an important step in the development of therapeutic applications for immunoproteasome diseases.
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Please refer to the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details of the methods.
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All statistical analyses were performed using Excel or R software programs. "n" stands for the number of independent experimental replications. The values are presented as the mean ± SD. Statistical significance was evaluated using either Student\'s t test or the Wilcoxon rank-sum test.
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